The place and role of oral microflora in the pathogenesis of oral mucositis in malignant neoplasms (literature review)
- Authors: Zavyalov A.A.1, Tyryshkin A.I.1, Olesova V.N.1, Pashchenko N.A.1, Gurkova M.M.2,3
-
Affiliations:
- State Research Center – Burnasyan Federal Medical Biophysical Center
- Sechenov First Moscow State Medical University (Sechenov University)
- Research and Production Center «Micromir»
- Issue: Vol 25, No 4 (2023)
- Pages: 525-531
- Section: CLINICAL ONCOLOGY
- URL: https://journals.rcsi.science/1815-1434/article/view/252446
- DOI: https://doi.org/10.26442/18151434.2023.4.202544
- ID: 252446
Cite item
Full Text
Abstract
Background. Oral mucositis (OM) is one of the most frequent complications of systemic drug therapy of oncological diseases. Clinically, the disease manifests itself in the form of erythema and ulceration of the non-corneating mucous membrane. Although this condition is self-healing, it can affect the conduct of comprehensive antitumor treatment. Currently, the pathophysiological model of the development of OM is supplemented with new data obtained during studies of the oral microflora. Antitumor treatment can lead to changes in the composition of the resident oral microflora and it is quite possible that the changes that occur may affect the development of damage to the oral mucosa. The expansion of knowledge in this area allows researchers to look for new ways to include oral microbiota in OM management strategies.
Aim. To summarize and update the accumulated data regarding the role of the oral microbiota in the pathogenesis of OM in patients with malignant neoplasms.
Materials and methods. Literature search was performed in Medline, Cochrane Library, Elibrary and Pubmed, including publications demonstrating the current ability to assess the impact of the oral microbiome on OM, as well as developments in this area relating to OM management.
Results. In the review the current views on the position of the oral microbiome in the pathogenesis of OM were highlighted and the promising directions for the use of agents influencing the state of the oral microbiota in various strategies to control this disease were emphasised.
Conclusion. A better understanding of the pathogenesis of OM and the inclusion of new factors, such as the oral microbiome, into the picture of pathogenesis is likely to enable the formation of more effective management strategies for this disease in the future. This direction seems very promising, and developments in this area show promising results.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Aleksander A. Zavyalov
State Research Center – Burnasyan Federal Medical Biophysical Center
Author for correspondence.
Email: azav06@mail.ru
ORCID iD: 0000-0003-1825-1871
SPIN-code: 5087-2394
D. Sci. (Med.), Prof.
Russian Federation, MoscowAleksandr I. Tyryshkin
State Research Center – Burnasyan Federal Medical Biophysical Center
Email: azav06@mail.ru
SPIN-code: 3473-9049
Clinical Resident
Russian Federation, MoscowValentina N. Olesova
State Research Center – Burnasyan Federal Medical Biophysical Center
Email: azav06@mail.ru
ORCID iD: 0000-0002-3461-9317
SPIN-code: 6851-5618
D. Sci. (Med.), Prof., State Research Center
Russian Federation, MoscowNataliya A. Pashchenko
State Research Center – Burnasyan Federal Medical Biophysical Center
Email: azav06@mail.ru
SPIN-code: 5056-4361
Graduate Student
Russian Federation, Moscow
Marina M. Gurkova
Sechenov First Moscow State Medical University (Sechenov University); Research and Production Center «Micromir»
Email: azav06@mail.ru
ORCID iD: 0000-0001-6473-9566
SPIN-code: 3473-9160
Master's student, Deputy General Director
Russian Federation, Moscow; MoscowReferences
- Vera-Llonch M, Oster G, Ford CM, et al. Oral mucositis and outcomes of allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies. Support Care Cancer. 2007;15(5):491-6. doi: 10.1007/s00520-006-0176-9
- Murphy BA, Beaumont JL, Isitt J, et al. Mucositis-related morbidity and resource utilization in head and neck cancer patients receiving radiation therapy with or without chemotherapy. J Pain Symptom Manage. 2009;38(4):522-32. doi: 10.1016/j.jpainsymman.2008.12.004
- Peterson DE, Srivastava R, Lalla RV. Oral mucosal injury in oncology patients: perspectives on maturation of a field. Oral Dis. 2015;21(2):133-41. doi: 10.1111/odi.12167
- Hong BY, Sobue T, Choquette L, et al. Chemotherapy-induced oral mucositis is associated with detrimental bacterial dysbiosis. Microbiome. 2019;7(1):66. doi: 10.1186/s40168-019-0679-5
- Sonis ST. New thoughts on the initiation of mucositis. Oral Dis. 2010;16(7): 597-600.
- Rice DH, Gill G. The effect of irradiation upon the bacterial flora in patients with head and neck cancer. Laryngoscope. 1979;89(11):1839-41. doi: 10.1288/00005537-197911000-00018
- Vanhoecke B, De Ryck T, Stringer A, et al. Microbiota and their role in the pathogenesis of oral mucositis. Oral Dis. 2015;21(1):17-30. doi: 10.1111/odi.12224
- Groeger S, Meyle J. Oral Mucosal Epithelial Cells. Front Immunol. 2019;10:208. doi: 10.3389/fimmu.2019.00208
- Li Y, Deng SL, Lian ZX, Yu K. Roles of Toll-Like Receptors in Nitroxidative Stress in Mammals Cells. 2019;8(6):576. doi: 10.3390/cells8060576
- Rauta PR, Samanta M, Dash HR, et al. Toll-like receptors (TLRs) in aquatic animals: signaling pathways, expressions and immune responses. Immunol Lett. 2014;158(1-2):14-24. doi: 10.1016/j.imlet.2013.11.013
- McClure R, Massari P. TLR-Dependent Human Mucosal Epithelial Cell Responses to Microbial Pathogens. Front Immunol. 2014;5. doi: 10.3389/fimmu.2014.00386
- Ji L, Hao S, Wang J, et al. Roles of Toll-Like Receptors in Radiotherapy- and Chemotherapy-Induced Oral Mucositis: A Concise Review. Front Cell Infect Microbiol. 2022;12:831387. doi: 10.3389/fcimb.2022.831387
- Nguyen S, Baker K, Padman BS, et al. Bacteriophage Transcytosis Provides a Mechanism To Cross Epithelial Cell Layers. mBio. 2017;8(6):e01874-17. doi: 10.1128/mBio.01874-17
- Vasconcelos RM, Sanfilippo N, Paster BJ, et al. Host-Microbiome Cross-talk in Oral Mucositis. J Dent Res. 2016;95(7):725-33. doi: 10.1177/0022034516641890
- Saunders DP, Epstein JB, Elad S, et al; Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients. Support Care Cancer. 2013;21(11):3191-207. doi: 10.1007/s00520-013-1871-y
- Laheij AM, van Loveren C, Deng D, de Soet JJ. The impact of virulence factors of Porphyromonas gingivalis on wound healing in vitro. J Oral Microbiol. 2015;7:27543.
- Laheij AM, de Soet JJ, von dem Borne PA, et al. Oral bacteria and yeasts in relationship to oral ulcerations in hematopoietic stem cell transplant recipients. Support Care Cancer. 2012;20(12):3231-40. doi: 10.1007/s00520-012-1463-2
- Sonis ST. The Chicken or the Egg? Changes in Oral Microbiota as Cause or Consequence of Mucositis During Radiation Therapy. EBioMedicine. 2017;18:7-8. doi: 10.1016/j.ebiom.2017.03.017
- Zhu XX, Yang XJ, Chao YL, et al. The Potential Effect of Oral Microbiota in the Prediction of Mucositis During Radiotherapy for Nasopharyngeal Carcinoma. EBioMedicine. 2017;18:23-31. doi: 10.1016/j.ebiom.2017.02.002
- De Ryck T, Vanlancker E, Grootaert C, et al. Microbial inhibition of oral epithelial wound recovery: potential role for quorum sensing molecules? AMB Express. 2015;5:27. doi: 10.1186/s13568-015-0116-5
- Hong CHL, Gueiros LA, Fulton JS, et al. Systematic Review of Basic Oral Care for the Management of Oral Mucositis in Cancer Patients and Clinical Practice Guidelines. Support Care Cancer. 2019;27(10):3949-67. doi: 10.1007/s00520-019-04848-4
- Cinausero M, Aprile G, Ermacora P, et al. New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury. Front Pharmacol. 2017;8:354. doi: 10.3389/fphar.2017.00354
- Clarkson JE. Interventions for treating oral mucositis for patients with cancer receiving treatment. The Cochrane Collaboration, 2010.
- Panebianco C, Latiano T, Pazienza V. Microbiota Manipulation by Probiotics Administration as Emerging Tool in Cancer Prevention and Therapy. Front Oncol. 2020;10:679. doi: 10.3389/fonc.2020.00679
- Perales-Puchalt A, Perez-Sanz J, Payne KK, et al. Frontline Science: Microbiota reconstitution restores intestinal integrity after cisplatin therapy. J Leukoc Biol. 2018;103(5):799-805. doi: 10.1002/JLB.5HI1117-446RR
- Kato S, Hamouda N, Kano Y, et al. Probiotic Bifidobacterium bifidum G9-1 attenuates 5-fluorouracil-induced intestinal mucositis in mice via suppression of dysbiosis-related secondary inflammatory responses. Clin Exp Pharmacol Physiol. 2017;44(10):1017-25. doi: 10.1111/1440-1681.12792
- Suez J, Zmora N, Zilberman-Schapira G, et al. Post-Antibiotic Gut Mucosal Microbiome Reconstitution Is Impaired by Probiotics and Improved by Autologous FMT. Cell. 2018;174(6):1406-23.e16. doi: 10.1016/j.cell.2018.08.047
- Cosseau C, Devine DA, Dullaghan E, et al. The commensal Streptococcus salivarius K12 downregulates the innate immune responses of human epithelial cells and promotes host-microbe homeostasis. Infect Immun. 2008;76(9):4163-75. doi: 10.1128/IAI.00188-08
- Wescombe PA, Hale JD, Heng NC, Tagg JR. Developing oral probiotics from Streptococcus salivarius. Future Microbiol. 2012;7(12):1355-71. doi: 10.2217/fmb.12.113
- Burton JP, Chilcott CN, Moore CJ, et al. A preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodour parameters. J Appl Microbiol. 2006;100(4):754-64. doi: 10.1111/j.1365-2672.2006.02837.x
- Wang Y, Li J, Zhang H, et al. Probiotic Streptococcus salivarius K12 Alleviates Radiation-Induced Oral Mucositis in Mice. Front Immunol. 2021;12:684824. doi: 10.3389/fimmu.2021.684824
- Barr JJ, Auro R, Furlan M, et al. Bacteriophage adhering to mucus provide a non-host-derived immunity. Proc Natl Acad Sci U S A. 2013;110(26):10771-6. doi: 10.1073/pnas.1305923110